Predicting Psoriasis Relapse After Stopping Biologic Therapy

Explore a recent 12-year study on psoriasis patients who discontinued biologic therapy, highlighting key factors that predict the time to relapse 

For patients with moderate-to-severe psoriasis, biologic therapies have become a cornerstone of treatment, providing significant relief and improved quality of life. However, what happens when biologic therapy is discontinued after a patient achieves remission? Understanding the risk of relapse and predicting the timing of that relapse can be crucial for both patients and their dermatologists when making decisions about long-term treatment plans. A recent study published in the American Journal of Clinical Dermatology sheds light on this topic, offering insights into how biologic therapy withdrawal impacts psoriasis relapse and what factors influence the time to relapse.

The Study: A Long-Term Look at Biologic Therapy Withdrawal

This multicenter cohort study, conducted over 12 years and across six dermatology centers, followed 991 episodes where psoriasis patients discontinued biologic therapy after achieving clinical remission. Clinical remission was defined as a 50% or greater improvement in the Psoriasis Area and Severity Index (PASI) score, with the patient achieving a PASI score of less than 10 before withdrawing from biologics.

The researchers aimed to predict how long patients remained in remission after discontinuing biologics and to identify factors that influence the time to relapse. A range of biologics was studied, including interleukin (IL)-23 inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, and tumor necrosis factor-alpha (TNF-α) inhibitors.

Key Findings: What Influences Psoriasis Relapse After Biologic Therapy?

1. Previous Withdrawals Lead to Shorter Remission Times The study found that with each subsequent withdrawal from biologic therapy, the time to relapse decreased significantly. In other words, patients who had withdrawn from biologics multiple times tended to relapse faster after each subsequent withdrawal.
2. Type of Biologic Matters Not all biologics performed the same when it came to maintaining remission after withdrawal. The study showed that patients who had been on IL-23 inhibitors experienced the longest time to relapse, followed by IL-12/23 inhibitors, IL-17 inhibitors, and finally, TNF-α inhibitors. These findings are valuable for dermatologists and patients looking to make informed decisions about which biologic to choose, especially when considering long-term treatment plans and the possibility of therapy discontinuation.
3. Other Predictors of Relapse Several other factors were identified as predictors of relapse, including:
   
   • Number of Prior Withdrawals: Patients who had withdrawn from biologics previously had a shorter time to relapse.
   • Time to Achieve PASI 50: Patients who took longer to achieve a 50% reduction in their PASI score after starting biologic therapy had a higher risk of early relapse.
   • PASI Score at Withdrawal: A higher PASI score at the time of biologic withdrawal was associated with a shorter time to relapse.
   • Maximum PASI Improvement: Patients who had the highest improvement in their PASI score while on biologic therapy were more likely to stay in remission for longer.

Why These Findings Matter for Psoriasis Treatment

For patients with moderate-to-severe psoriasis, these findings provide essential insights that can guide discussions with their dermatologist about treatment plans, especially when considering the discontinuation of biologic therapy. The information can be used to make personalized decisions about whether to stop treatment, how long to expect remission, and which biologic may offer the longest protection against relapse.

This study also highlights that while biologic therapy is effective, repeated cycles of discontinuation and re-initiation may reduce the efficacy of treatment over time. For patients considering intermittent biologic therapy or those contemplating stopping treatment after remission, these results underscore the importance of carefully weighing the risks and benefits.

Conclusion

This 12-year study offers important insights into psoriasis relapse after biologic therapy withdrawal, providing valuable information for both patients and dermatologists. By understanding the factors that influence relapse, such as the type of biologic used and the patient's treatment history, individuals can make more informed choices about their psoriasis management. Whether continuing with biologic therapy or considering withdrawal, the goal remains the same: to achieve and maintain the best possible quality of life while minimizing the impact of psoriasis.

Consulting with a board-certified dermatologist, like Dr. Yoon Cohen at Skin Clinic in Scottsdale, Arizona, ensures you receive the most accurate diagnosis and tailored treatment plan for managing psoriasis. Psoriasis can present in various forms, including plaque, guttate, inverse, and pustular, which may be mistaken for other skin conditions such as eczema, fungal infections, or dermatitis. Each of these conditions requires a distinct treatment approach.

A board-certified dermatologist has the expertise to differentiate between these skin conditions and develop a personalized treatment plan that suits your specific needs. Whether it's selecting the appropriate biologic therapy, topical treatment, or lifestyle adjustments, their specialized knowledge ensures that your psoriasis is managed effectively and efficiently.

Direct pay dermatology clinics, like Skin Clinic, provide numerous advantages for psoriasis patients, including:

• Faster access to specialist care

• Convenient scheduling, telemedicine options, and 24/7 online booking

• Comprehensive, longer office visits customized to your needs

• A strong, direct patient-provider relationship for ongoing care

• Transparent and affordable payment options without insurance limitations

By choosing a direct pay model, psoriasis patients receive high-quality, uninterrupted care, ensuring the best possible management of their skin condition.

Ready to see Dr. Cohen? Call us at 480-944-5096 to schedule your appointment at our Scottsdale office.